Literature DB >> 29274432

A mouse model of DEPDC5-related epilepsy: Neuronal loss of Depdc5 causes dysplastic and ectopic neurons, increased mTOR signaling, and seizure susceptibility.

Christopher J Yuskaitis1, Brandon M Jones2, Rachel L Wolfson3, Chloe E Super2, Sameer C Dhamne2, Alexander Rotenberg4, David M Sabatini5, Mustafa Sahin6, Annapurna Poduri7.   

Abstract

DEPDC5 is a newly identified epilepsy-related gene implicated in focal epilepsy, brain malformations, and Sudden Unexplained Death in Epilepsy (SUDEP). In vitro, DEPDC5 negatively regulates amino acid sensing by the mTOR complex 1 (mTORC1) pathway, but the role of DEPDC5 in neurodevelopment and epilepsy has not been described. No animal model of DEPDC5-related epilepsy has recapitulated the neurological phenotypes seen in patients, and germline knockout rodent models are embryonic lethal. Here, we establish a neuron-specific Depdc5 conditional knockout mouse by cre-recombination under the Synapsin1 promotor. Depdc5flox/flox-Syn1Cre (Depdc5cc+) mice survive to adulthood with a progressive neurologic phenotype that includes motor abnormalities (i.e., hind limb clasping) and reduced survival compared to littermate control mice. Depdc5cc+ mice have larger brains with increased cortical neuron size and dysplastic neurons throughout the cortex, comparable to the abnormal neurons seen in human focal cortical dysplasia specimens. Depdc5 results in constitutive mTORC1 hyperactivation exclusively in neurons as measured by the increased phosphorylation of the downstream ribosomal protein S6. Despite a lack of increased mTORC1 signaling within astrocytes, Depdc5cc+ brains show reactive astrogliosis. We observed two Depdc5cc+ mice to have spontaneous seizures, including a terminal seizure. We demonstrate that as a group Depdc5cc+ mice have lowered seizure thresholds, as evidenced by decreased latency to seizures after chemoconvulsant injection and increased mortality from pentylenetetrazole-induced seizures. In summary, our neuron-specific Depdc5 knockout mouse model recapitulates clinical, pathological, and biochemical features of human DEPDC5-related epilepsy and brain malformations. We thereby present an important model in which to study targeted therapeutic strategies for DEPDC5-related conditions.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Conditional knockout; DEPDC5; Familial focal epilepsy; Focal cortical dysplasia; Megalencephaly; Seizures; mTOR

Mesh:

Substances:

Year:  2017        PMID: 29274432      PMCID: PMC5803417          DOI: 10.1016/j.nbd.2017.12.010

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  46 in total

Review 1.  The neurology of mTOR.

Authors:  Jonathan O Lipton; Mustafa Sahin
Journal:  Neuron       Date:  2014-10-22       Impact factor: 17.173

2.  Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex.

Authors:  Stefanie Anderl; Megan Freeland; David J Kwiatkowski; June Goto
Journal:  Hum Mol Genet       Date:  2011-09-01       Impact factor: 6.150

3.  Graded loss of tuberin in an allelic series of brain models of TSC correlates with survival, and biochemical, histological and behavioral features.

Authors:  Elizabeth Yuan; Peter T Tsai; Emily Greene-Colozzi; Mustafa Sahin; David J Kwiatkowski; Izabela A Malinowska
Journal:  Hum Mol Genet       Date:  2012-06-29       Impact factor: 6.150

4.  Pten is essential for embryonic development and tumour suppression.

Authors:  A Di Cristofano; B Pesce; C Cordon-Cardo; P P Pandolfi
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

5.  Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.

Authors:  Lynsey Meikle; Kristen Pollizzi; Anna Egnor; Ioannis Kramvis; Heidi Lane; Mustafa Sahin; David J Kwiatkowski
Journal:  J Neurosci       Date:  2008-05-21       Impact factor: 6.167

6.  Exome-based analysis of cardiac arrhythmia, respiratory control, and epilepsy genes in sudden unexpected death in epilepsy.

Authors:  Richard D Bagnall; Douglas E Crompton; Slavé Petrovski; Lien Lam; Carina Cutmore; Sarah I Garry; Lynette G Sadleir; Leanne M Dibbens; Anita Cairns; Sara Kivity; Zaid Afawi; Brigid M Regan; Johan Duflou; Samuel F Berkovic; Ingrid E Scheffer; Christopher Semsarian
Journal:  Ann Neurol       Date:  2016-02-02       Impact factor: 10.422

7.  Mutations in the mammalian target of rapamycin pathway regulators NPRL2 and NPRL3 cause focal epilepsy.

Authors:  Michael G Ricos; Bree L Hodgson; Tommaso Pippucci; Akzam Saidin; Yeh Sze Ong; Sarah E Heron; Laura Licchetta; Francesca Bisulli; Marta A Bayly; James Hughes; Sara Baldassari; Flavia Palombo; Margherita Santucci; Stefano Meletti; Samuel F Berkovic; Guido Rubboli; Paul Q Thomas; Ingrid E Scheffer; Paolo Tinuper; Joel Geoghegan; Andreas W Schreiber; Leanne M Dibbens
Journal:  Ann Neurol       Date:  2015-12-12       Impact factor: 10.422

8.  SZT2 dictates GATOR control of mTORC1 signalling.

Authors:  Min Peng; Na Yin; Ming O Li
Journal:  Nature       Date:  2017-02-15       Impact factor: 49.962

9.  Replicable in vivo physiological and behavioral phenotypes of the Shank3B null mutant mouse model of autism.

Authors:  Sameer C Dhamne; Jill L Silverman; Alexander Rotenberg; Jacqueline N Crawley; Mustafa Sahin; Chloe E Super; Stephen H T Lammers; Mustafa Q Hameed; Meera E Modi; Nycole A Copping; Michael C Pride; Daniel G Smith
Journal:  Mol Autism       Date:  2017-06-15       Impact factor: 7.509

10.  High-throughput discovery of novel developmental phenotypes.

Authors:  Mary E Dickinson; Ann M Flenniken; Xiao Ji; Lydia Teboul; Michael D Wong; Jacqueline K White; Terrence F Meehan; Wolfgang J Weninger; Henrik Westerberg; Hibret Adissu; Candice N Baker; Lynette Bower; James M Brown; L Brianna Caddle; Francesco Chiani; Dave Clary; James Cleak; Mark J Daly; James M Denegre; Brendan Doe; Mary E Dolan; Sarah M Edie; Helmut Fuchs; Valerie Gailus-Durner; Antonella Galli; Alessia Gambadoro; Juan Gallegos; Shiying Guo; Neil R Horner; Chih-Wei Hsu; Sara J Johnson; Sowmya Kalaga; Lance C Keith; Louise Lanoue; Thomas N Lawson; Monkol Lek; Manuel Mark; Susan Marschall; Jeremy Mason; Melissa L McElwee; Susan Newbigging; Lauryl M J Nutter; Kevin A Peterson; Ramiro Ramirez-Solis; Douglas J Rowland; Edward Ryder; Kaitlin E Samocha; John R Seavitt; Mohammed Selloum; Zsombor Szoke-Kovacs; Masaru Tamura; Amanda G Trainor; Ilinca Tudose; Shigeharu Wakana; Jonathan Warren; Olivia Wendling; David B West; Leeyean Wong; Atsushi Yoshiki; Daniel G MacArthur; Glauco P Tocchini-Valentini; Xiang Gao; Paul Flicek; Allan Bradley; William C Skarnes; Monica J Justice; Helen E Parkinson; Mark Moore; Sara Wells; Robert E Braun; Karen L Svenson; Martin Hrabe de Angelis; Yann Herault; Tim Mohun; Ann-Marie Mallon; R Mark Henkelman; Steve D M Brown; David J Adams; K C Kent Lloyd; Colin McKerlie; Arthur L Beaudet; Maja Bućan; Stephen A Murray
Journal:  Nature       Date:  2016-09-14       Impact factor: 49.962

View more
  40 in total

1.  Chronic mTORC1 inhibition rescues behavioral and biochemical deficits resulting from neuronal Depdc5 loss in mice.

Authors:  Christopher J Yuskaitis; Leigh-Ana Rossitto; Sarika Gurnani; Elizabeth Bainbridge; Annapurna Poduri; Mustafa Sahin
Journal:  Hum Mol Genet       Date:  2019-09-01       Impact factor: 6.150

2.  Delving Deeper into DEPDC5.

Authors:  Laura A Jansen
Journal:  Epilepsy Curr       Date:  2018 May-Jun       Impact factor: 7.500

3.  Skeletal muscle-specific knockout of DEP domain containing 5 protein increases mTORC1 signaling, muscle cell hypertrophy, and mitochondrial respiration.

Authors:  Ted G Graber; Christopher S Fry; Camille R Brightwell; Tatiana Moro; Rosario Maroto; Nisha Bhattarai; Craig Porter; Maki Wakamiya; Blake B Rasmussen
Journal:  J Biol Chem       Date:  2019-01-11       Impact factor: 5.157

Review 4.  Nutrient regulation of mTORC1 at a glance.

Authors:  Kendall J Condon; David M Sabatini
Journal:  J Cell Sci       Date:  2019-11-13       Impact factor: 5.285

5.  Prevention of premature death and seizures in a Depdc5 mouse epilepsy model through inhibition of mTORC1.

Authors:  Lindsay K Klofas; Brittany P Short; Chengwen Zhou; Robert P Carson
Journal:  Hum Mol Genet       Date:  2020-05-28       Impact factor: 6.150

6.  Neuron-Type Specific Loss of CDKL5 Leads to Alterations in mTOR Signaling and Synaptic Markers.

Authors:  Ethan Schroeder; Li Yuan; Eunju Seong; Cheryl Ligon; Nicholas DeKorver; C B Gurumurthy; Jyothi Arikkath
Journal:  Mol Neurobiol       Date:  2018-10-04       Impact factor: 5.590

7.  Somatic Depdc5 deletion recapitulates electroclinical features of human focal cortical dysplasia type IIA.

Authors:  Shuntong Hu; Robert C Knowlton; Brendon O Watson; Katarzyna M Glanowska; Geoffrey G Murphy; Jack M Parent; Yu Wang
Journal:  Ann Neurol       Date:  2018-08-06       Impact factor: 10.422

8.  Neuron-specific Kv1.1 deficiency is sufficient to cause epilepsy, premature death, and cardiorespiratory dysregulation.

Authors:  Krystle Trosclair; Hemangini A Dhaibar; Nicole M Gautier; Vikas Mishra; Edward Glasscock
Journal:  Neurobiol Dis       Date:  2020-01-21       Impact factor: 5.996

Review 9.  GATORopathies: The role of amino acid regulatory gene mutations in epilepsy and cortical malformations.

Authors:  Philip H Iffland; Vincent Carson; Angelique Bordey; Peter B Crino
Journal:  Epilepsia       Date:  2019-10-17       Impact factor: 5.864

Review 10.  mTOR at the nexus of nutrition, growth, ageing and disease.

Authors:  Grace Y Liu; David M Sabatini
Journal:  Nat Rev Mol Cell Biol       Date:  2020-01-14       Impact factor: 94.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.